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 Figure: The excess risk of patient-reported urinary incontinence 
according to the mean dose model based on absorbed dose (solid 
black) and fractionation-corrected dose into equivalent 2-Gy fractions 
using the Linear-quadratic model with a/b=3 for late effects (solid 
grey). Dotted lines indicate 68% confidence intervals. 
Conclusions: Efforts to maintain the mean absorbed urinary bladder 
dose below 29 Gy (mean fractionation-corrected dose of 22 Gy3) in 
prostate-cancer treatments with EBRT may keep the prevalence of 
patient-reported urinary incontinence below 10%. Both dose 
representations provide similar results for the clinically relevant range 
of dose values. 
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Purpose/Objective: In carbon ion radiotherapy, the increased relative 
biological effectiveness (RBE) has to be modeled to arrive at the 
biologically effective dose. In this study, the RBE of carbon ions was 
measured in the spinal cord and the results were compared to 
predictions of the local effect model (LEM) as well as to clinical data 
on normal tissue reactions. 
Materials and Methods: The cranial part of the spinal cord of rats was 
irradiated with 1, 2, 6 or 18 fractions (Fx) of photons or carbon ions, 
respectively [1]. Carbon ion irradiations were performed in the 
plateau region (13 keV/mm) or in the middle of a 1 cm spread-out 
Bragg peak (SOBP, 125 keV/mm). Biological endpoint was the onset of 
paresis grade II within 10 months after irradiation. Dose response 
curves were measured and RBEs were calculated based on D50 (dose at 
50% complication probability). In addition α/β-values were 
determined. 
Results: The RBE-values were 1.44±0.08, 1.37±0.05, 1.33±0.02 and 
1.42±0.02 for the plateau- and 1.77±0.06, 2.17±0.06, 2.97±0.05, and 
5.04±0.08 for the peak-irradiations (1, 2, 6, and 18 Fx, respectively). 
The respective predictions by the clinically applied local effect model 
(LEM I) were 1.14, 1.19, 1.37, and 1.72 for the plateau- and 1.28, 
1.61, 2.35, and 3.80 for the peak irradiations, respectively. The α/β-
values were 2.8±0.4 Gy for photons, 2.1±0.4 Gy for the plateau and 
37.0±5.3 Gy for the peak-irradiations, respectively. 
  
Conclusions: Carbon ion irradiations of the spinal cord are 
significantly more effective in the Bragg-peak than in the plateau 
region. A significant fractionation effect was found only for the 
plateau. The clinically applied LEM-version correctly describes the 
main features although it generally underestimated the RBE in the 
Bragg-peak by about 25% (fig. 1). In contrast, a retrospective clinical 
study determined the biologically equivalent tolerance dose for 5% 
probability of MRI-detected temporal lobe reactions (D5) to be 
68.8±3.3 GyE [2]. This value complies well with clinical experience 
from photon therapy and hence, there is no indication for a significant 
underestimation of the RBE in patients. Meanwhile, improved versions 
of the LEM (LEM II-IV) are available [3,4], which show good agreement 
with the measured RBE-values for the peak region. To clarify the 
relation between experimental, clinical and calculated RBEs, the 
clinical data have to be reanalyzed using LEM IV. Further work is 
ongoing to systematically determine RBE and α/β-values at several 
positions in an extended SOBP corresponding to different LET-values. 
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Purpose/Objective: Post radiation therapy (RT) chronic otitis media 
(COM) has been implicated with incidence of sensory neural hearing 
loss (SNHL) in head & neck cancer (HNCa) patients. The goal of this 
study is to examine the association and evaluate the effect of post-RT 
COM on the dose parameters associated with post-RT SNHL in head 
and neck cancer (HNCa) patients receiving RT ± chemotherapy 
(chemo) using logistic modeling. 
Materials and Methods: Radiation oncology and otolaryngology 
records of 395 HNCa patients who received RT±Chemo were 
retrospectively reviewed to code incidence of post-RT COM and SNHL 
using air & bone conduction thresholds for high frequency hearing at 4 
kHz. The criteria for SNHL was 10 dB increase in hearing threshold 
with respect to baseline evaluation. Median follow up was 5.7 Years 
(range: 0.5-30 years). Mean doses received by the middle ear and 
cochlea were estimated by treatment plan evaluation and used for 
analysis. A Fisher's exact test used to determine association between 
post-RT COM and SNHL. A logistic function was used to describe the 
dose response for incidence of SNHL for patients treated with RT only 
and those with Chemo+RT. In each group the model was fitted first to 
all patients (including those with post RT COM) treated with the 
specific modality (RT only or RT+Chemo) and then to the subset of the 
patients treated with that modality who did not have occurrence of 
post-RT COM. Maximum likelihood method was used to optimize the 
fit. 
Results: Post-RT COM was observed in 31.5% patients. Fisher's exact 
test indicated that post-RT COM was significant in the incidence of 
SNHL (p <0.001). The estimated TD5 & TD10 for RT Only group were 
34.3 Gy, 41.9 Gy when all the patients were included and those for 
subset of patients without post-RT COM were 37.1 Gy, 44.7 Gy. Those 
for Chemo+RT group were 29.8 Gy, 37.4 Gy when all patients included 
and those for subset of patients without post-RT COM were 38.1 Gy, 
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43.6 Gy. The estimated TD50 & γ50 for RT Only group were 64.2 Gy & 
1.58 when all the patients were included and those for subset of 
patients without post-RT COM were 67 Gy & 1.65. Those for 
Chemo+RT group were 59.7 Gy & 1.47 when all patients included and 
those for subset of patients without post-RT COM were 59.9 Gy & 
2.02. 
Conclusions: Post RT COM is statistically significant for incidence of 
SNHL. The decrease in TD5 and TD10 for post-RT SNHL in the dataset 
that included patients with post-RT COM suggest that occurrence of 
post-RT COM may decrease the dose for onset of post-RT SNHL. The 
analysis suggest that subset of patients with post-RT COM may be a 
high risk group for post-RT SNHL. 
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Purpose/Objective: As most patients survive early-stage prostate 
cancer after treatment, quality of life outcome has emerged as an 
important factor to consider in treatment decisions. Radiation-
induced genitourinary (GU) symptoms may impair patients' quality of 
life and still occur with a 5-year actuarial risk of 20%. Moreover, the 
incidence does not seem to plateau and may be expected many years 
after treatment. Therefore, the purpose of this study was to construct 
multi-component models for the prediction of late GU sequellae in 
prostate cancer patients. 
Materials and Methods: Data were available for 265 prostate cancer 
patients treated with primary or post-operative intensity-modulated 
radiation therapy. The median follow-up was 4 years (0.5-13 years). 
Toxicity was scored using an in-house developed toxicity scale. For 
model building, clinical data (age, smoking, diabetes,hypertension, 
pre-treatment symptoms, transurethral resection of the prostate 
(TUR)), treatment data (lymph node dissection, androgen deprivation, 
radical prostatectomy), dosimetric parameters (doses delivered to to 
the clinical target volume (CTV) and the bladder (B)) and 343 genetic 
polymorphisms were considered. Selection of parameters for the 
predicting model was achieved by lasso logistic regression followed by 
classic logistic regression for unbiased estimation of the coefficients. 
Missing data were handled by a stochastic expectation-maximisation 
(EM) algorithm. Performance of the model was expressed as the area 
under the curve (AUC) of the receiver operating characteristic (ROC) 
curve and as the false-negative rate (FNR) and false-positive rate 
(FPR) in the optimal point on the ROC curve. 
Results: In our series, grade ≥ 2 nocturia and hematuria are the most 
prevalent GU symptoms and encompass more than 50% of the grade ≥ 
2 symptoms presented. Late nocturia occurred in 29 of the 265 
patients (11%). The final prediction model has an AUC of 0.81 and 
contains the minimal CTV dose, the CTV volume, the volume of the 
bladder receiving at least 65 Gy, the presence of acute grade 2 
nocturia symptoms and polymorphisms rs1799983 (NOS3), rs104585 
(CASP8), rs4808611 (NR2F6) and rs6163 (CYP17A1). The FNR and FPR 
are, respectively, 17% and 27%. A total of 14% of the patients (n=36) 
developed late radiation-induced hematuria. The prediction model for 
late hematuria has an AUC of 0.79 and consists of seven parameters: 
the volume of the bladder receiving at least 75 Gy, age at last follow-
up visit, prior TUR and rs3931914 (HMGRC), rs2293054 (NOS1), 
rs708598 (PTGER2) and rs845552 (EGFR). The FNR and FPR are 28% and 
29%, respectively. 
Conclusions: Combining clinical, treatment, dosimetric and genetic 
factors has the potential to improve the prediction of late urinary 
toxicity. External validation of the prediction models is necessary 
before implementing these models in the clinic. 
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Purpose/Objective: Fas ligand (FASL, also known as APO-1L, CD95LG, 
CD178, TNFSF6) triggers the apoptotic cell-death by cross-linking with 
its receptor FAS (TNFSF6, CD95/APO-1), and after irradiation, 
expression of FAS and FASL is increased and has been associated with 
radiation-induced delayed cell death. In the present prospective 
study, we analyzed the role of common polymorphisms in the genes 
for FAS and FASL for the development of late toxicity after 
radiotherapy for prostate cancer.  
Materials and Methods: The association of FAS (-1377G>A, rs2234767 
and -670A>G, rs1800682) and FASL (-844C>T, rs763110) gene 
polymorphisms with high-grade late rectal and/or urinary toxicity 
(defined as late toxicity EORTC/RTOG grade≥2) was analyzed using 
607 prostate cancer patients treated with radiotherapy in curative 
intent. The selected polymorphisms were determined by 5´-nuclease 
(TaqMan) assays. 
Results: After a median follow-up time of 81 months, high-grade late 
rectal and/or urinary toxicity was observed in 175 patients (29.7%). In 
Kaplan-Meier analysis, the -844C>T polymorphism was significantly 
associated with high-grade late toxicity (p=0.007). In univariate Cox 
proportional hazard analysis, carriers of the -844C>T polymorphism 
were at decreased risk of high-grade late toxicity (HR=0.686, 95%CI 
0.541 - 0.87; p=0.002). In multivariate Cox regression analysis 
including clinical and dosimetric parameters as potential confounders, 
the -844C>T polymorphism in the FASL gene remained a predictive 
factor (HR=0.642, 95%CI 0.459 - 0.896; p=0.009). For the remaining 
analyzed polymorphisms no significant associations were found. 
Conclusions: We conclude that the FASL -844C>T polymorphism may 
be protective against the development of high-grade late toxicity 
after radiotherapy for prostate cancer.  
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Purpose/Objective: Acute mucositis is a serious dose-limiting side 
effect during and immediately after primary RT, concurrent 
chemoradiation (ChemoRT) or a combination of cetuximab and 
accelerated RT (bioradiation or BioRT) resulting in compromised oral 
intake due to pain and dysphagia. The purpose of this study was to 
identify pre treatment variables and DVH parameters that might 
predict acute mucositis grade 2-4 at the end of the treatment. 
Materials and Methods: This prospective study included 170 patients 
with head and neck squamous cell carcinoma (HNSSC) included in a 
standardized follow up program (SFP). Patients were treated with 
curative intent. Acute mucositis was assessed at baseline and at 
consecutive time points during (weekly) and after treatment. Acute 
mucositis was defined as grade 2-4 according the RTOG grading 
system. In all cases the oral cavity as well as parotid glands, 
submandibular glands, spinal cord and swallowing organs at risk were 
delineated on the planning CT scans. Dose volume histogram (DVH) 
parameters were collected as well as pre treatment variables. The 
predictive model was designed using a multiple logistic regression 
analysis. The primary endpoint was acute mucositis grade 2-4 assessed 
in the last week of the treatment. 
Results: The predictive model consisted of the pre treatment 
variables: concurrent chemoradiation (coefficient=1.93) and 
bioradiation (coefficient=1.33). The V60 (the volume of the oral cavity 
receiving ≤ 60 Gy) was the single statistically significant DVH 
parameter (coefficient=0.06) and was included in the model. The 
model performance was good expressed by the area under the curve 
(AUC = 0.83 (p=0.000)) and the Hosmer Lemeshow goodness-of-fit test 
(p=0.79). 
Conclusions: The severity of acute mucositis in the last week of 
primary RT, ChemoRT or BioRT in head and neck cancer patients can 
be predicted by two pre treatment variables and one DVH parameter 
(V60). The use of V60 can be helpful in IMRT optimization to reduce this 
side effect or select high-risk patients for intensified supportive care.  
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Purpose/Objective: To investigate if post-radiotherapy (RT) 
scintigraphy measurements of salivary glands manifest such 
